Eugeen M. Vanmechelen
R&d
Gent, VLG, Belgium
Gent, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Value of synaptic proteins as biomarkers in amyotrophic lateral sclerosis.
Journal: Brain communications
Published: January 15, 2026
Detecting amyloid-β pathology in subjective cognitive decline using plasma and CSF biomarkers.
Journal: EBioMedicine
Published: November 04, 2025
Associations of 18F-RO-948 tau PET with fluid AD biomarkers, Centiloid, and cognition in early AD continuum.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: July 18, 2025
Associations of 18 F-RO-948 Tau PET with Fluid AD Biomarkers, Centiloid, and Cognition in the Early AD Continuum.
Journal: medRxiv : the preprint server for health sciences
Published: July 17, 2025
Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].
Journal: The journal of prevention of Alzheimer's disease
Published: June 06, 2025
Plasma vesicle-associated membrane protein 2 and glial fibrillary acidic protein associate with synaptic density in older adults without dementia.
Journal: Brain communications
Published: March 16, 2025
Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer's disease and Parkinson's disease.
Journal: Alzheimer's research & therapy
Published: February 26, 2025
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease.
Journal: The journal of prevention of Alzheimer's disease
Published: November 26, 2024
Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers.
Journal: Alzheimer's research & therapy
Published: November 19, 2024
Novel CSF β-synuclein-specific assays signal early synaptic degeneration in Alzheimer's disease.
Journal: Alzheimer's research & therapy
Published: November 14, 2024
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer's disease, positive for plasma p-tau217.
Journal: Alzheimer's research & therapy
Published: September 13, 2024
Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologies.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: March 07, 2024
Last Updated: 09/26/2026